NEW YORK — French specialty diagnostics company Sebia said on Tuesday that it has acquired Zeus Scientific.
Financial and other terms of the deal were not disclosed.
Zeus develops and manufactures in vitro diagnostic immunoassays and related products for infectious and autoimmune diseases. In late 2020, the Branchburg, New Jersey-based company received Emergency Use Authorization from the US Food and Drug Administration for a test to detect antibodies against the SARS-CoV-2 virus.
Sebia said that the acquisition would help expand its presence in the US, as well as its capabilities and product portfolio in autoimmunity.
"There are many parallels in our respective R&D programs, as well as benefits for the development of our global commercial network," Sebia President and CEO Jean-Marc Chermette said in a statement. "With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market."